课题基金 / 基金详情

Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects

Vaccine and Monoclonal Antibody Studies in HIV-infected Subjects
HIV 感染者的疫苗和单克隆抗体研究
批准号：
8745627
负责人：
Barney Graham
金额：
$53.11万
依托单位：
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/8745627
关键词：
Active immunityAdverse effectsAnti-Retroviral AgentsAntibodiesClinicClinicalClinical ResearchClinical TrialsConduct Clinical TrialsDoseGoalsHIVHIV InfectionsHIV-1Immune responseImmunotherapeutic agentInfectionInfection ControlMedication ManagementMonoclonal AntibodiesPassive ImmunityPhasePreventionRegimenResearch Project GrantsTherapeutic StudiesUnited States National Institutes of HealthVaccinesbasehuman monoclonal antibodiesmethod developmentvaccine candidatevolunteer

项目摘要

项目成果

Barney Graham的其他基金

相似基金

相关文献

中文摘要
翻译
总结：该临床研究项目是针对HIV感染志愿者通过NIH临床中心VRC Clinic进行的临床试验进行的针对HIV的主动免疫（疫苗）和被动免疫（单克隆抗体）相关临床试验。 以下是迄今为止每项研究的简要摘要。 VRC 101（06-I-0056）是VRC开发的两种候选HIV-1疫苗的第一个I期治疗研究，并以初免-加强方案给药。 VRC 601（13-I-0189）是VRC开发的具有广泛HIV-1中和活性的人单克隆抗体在HIV感染志愿者中进行的第一项I期剂量递增研究。
英文摘要
Summary: This clinical research project is for clinical trials related to active immunity (vaccines) and passive immunity (monoclonal antibodies) directed against HIV that are evaluated in HIV-infected volunteers through clinical trials conducted by the VRC Clinic at the NIH Clinical Center. A brief summary of each study to date follows. VRC 101 (06-I-0056) was the first Phase I therapeutic study of two candidate HIV-1 vaccines developed by the VRC and administered in a prime-boost regimen. VRC 601 (13-I-0189) is the first Phase I dose-escalation study in HIV-infected volunteers of a human monoclonal antibody developed by the VRC with broad HIV-1 neutralizing activity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cellular Immune Responses to RSV infection in Mice
Rapid Development of Vaccines for Emerging Viruses
Factors Contributing To Immune-Enhanced Disease In The Pathogenesis of RSV
Vectors and Methods to Increase Immunogenicity during DNA Vaccination
海外基金